Wedbush Believes Juno Therapeutics (NASDAQ: JUNO) Won’t Stop Here

By Ryan Adsit

Wedbush analyst David Nierengarten upgraded Juno Therapeutics (NASDAQ: JUNO) to Buy today. The company’s shares closed yesterday at $36.48, close to its 52-week high of $37.50.

According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of 25.2% and a 49.2% success rate. Nierengarten covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Stemline Therapeutics Inc, and Voyager Therapeutics Inc.

Juno Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $36.

The company has a one year high of $37.50 and a one year low of $17.52. Currently, Juno Therapeutics has an average volume of 1.97M.

Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans E. Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, and Robert T.